endogenous peroxidase  (Agilent technologies)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86
    Name:
    PD L1 IHC 22C3 pharmDx for use with Dako Omnis
    Description:
    PD L1 IHC 22C3 pharmDx is a qualitative immunohistochemical assay using Monoclonal Mouse Anti PD L1 Clone 22C3 intended for use in the detection of PD L1 protein in formalin fixed paraffin embedded FFPE non small cell lung cancer NSCLC tissue using EnVision FLEX visualization system for use on Dako Omnis PD L1 protein expression in NSCLC is determined by using Tumor Proportion Score TPS which is the percentage of viable tumor cells showing partial or complete membrane staining at any intensity The specimen should be considered to have PD L1 expression if TPS 1 PD L1 IHC 22C3 pharmDx is indicated as an aid in identifying NSCLC patients for treatment with KEYTRUDA pembrolizumab See the KEYTRUDA product label for specific clinical circumstances guiding PD L1 testing PD L1 IHC 22C3 pharmDx on Dako Omnis The assay is a modular IHC assay for 60 tests The assay has been tailored especially with EnVision FLEX visualization system on the Dako Omnis instrument The complete assay consists of the following components to be ordered separately PD L1 IHC 22C3 pharmDx GE00621 5 for Dako Omnis Monoclonal Mouse Anti PD L1 Clone 22C3 RTU Dako Omnis with Negative Control Reagent EnVision FLEX High pH Dako Omnis GV80011 2 OR EnVision FLEX Mini Kit High pH Dako Omnis GV82311 2 EnVision FLEX Target Retrieval Solution Low pH 50x GV80511 2 EnVision FLEX Mouse Linker Dako Omnis GV82111 2 EnVision FLEX DAB Enhancer Dako Omnis GC80611 2 PD L1 Control Slides T139130 2 optional The assay requires Low pH Target Retrieval Mouse Linker and a DAB Enhancer but the PD L1 Control Slides are optional For countries outside of the United States see the local KEYTRUDA product label for approved indications and expression cutoff values to guide therapy PD L1 IHC 22C3 pharmDx is subject to an exclusive trademark license to Dako Denmark A S KEYTRUDA is a registered trademark of Merck Sharp Dohme Corp a subsidiary of Merck Co Inc
    Catalog Number:
    PD-L1-IHC-22C3-PHARMDX,-FOR-USE-WITH-DAKO-OMNIS
    Price:
    None
    Category:
    Products Dako Omnis Solution For Ihc Ish Pharmdx Kit For Dako Omnis Pharmdx Kit Pd L1 Ihc 22C3 Pharmdx For Use With Dako Omnis
    Buy from Supplier


    Structured Review

    Agilent technologies endogenous peroxidase
    PD L1 IHC 22C3 pharmDx is a qualitative immunohistochemical assay using Monoclonal Mouse Anti PD L1 Clone 22C3 intended for use in the detection of PD L1 protein in formalin fixed paraffin embedded FFPE non small cell lung cancer NSCLC tissue using EnVision FLEX visualization system for use on Dako Omnis PD L1 protein expression in NSCLC is determined by using Tumor Proportion Score TPS which is the percentage of viable tumor cells showing partial or complete membrane staining at any intensity The specimen should be considered to have PD L1 expression if TPS 1 PD L1 IHC 22C3 pharmDx is indicated as an aid in identifying NSCLC patients for treatment with KEYTRUDA pembrolizumab See the KEYTRUDA product label for specific clinical circumstances guiding PD L1 testing PD L1 IHC 22C3 pharmDx on Dako Omnis The assay is a modular IHC assay for 60 tests The assay has been tailored especially with EnVision FLEX visualization system on the Dako Omnis instrument The complete assay consists of the following components to be ordered separately PD L1 IHC 22C3 pharmDx GE00621 5 for Dako Omnis Monoclonal Mouse Anti PD L1 Clone 22C3 RTU Dako Omnis with Negative Control Reagent EnVision FLEX High pH Dako Omnis GV80011 2 OR EnVision FLEX Mini Kit High pH Dako Omnis GV82311 2 EnVision FLEX Target Retrieval Solution Low pH 50x GV80511 2 EnVision FLEX Mouse Linker Dako Omnis GV82111 2 EnVision FLEX DAB Enhancer Dako Omnis GC80611 2 PD L1 Control Slides T139130 2 optional The assay requires Low pH Target Retrieval Mouse Linker and a DAB Enhancer but the PD L1 Control Slides are optional For countries outside of the United States see the local KEYTRUDA product label for approved indications and expression cutoff values to guide therapy PD L1 IHC 22C3 pharmDx is subject to an exclusive trademark license to Dako Denmark A S KEYTRUDA is a registered trademark of Merck Sharp Dohme Corp a subsidiary of Merck Co Inc
    https://www.bioz.com/result/endogenous peroxidase/product/Agilent technologies
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    endogenous peroxidase - by Bioz Stars, 2021-04
    86/100 stars

    Images

    Related Articles

    Fluorescence In Situ Hybridization:

    Article Title: PD‐L1 expression in ROS1‐rearranged non‐small cell lung cancer: A study using simultaneous genotypic screening of EGFR, ALK, and ROS1
    Article Snippet: .. Additionally, the sample needed to have > 100 tumor cells for the PD‐L1 test and > 50 tumors cells for ALK and ROS1 FISH tests., In a tissue‐sparing manner, we also investigated an IHC panel including thyroid transcription factor 1 (TTF‐1), p63, p40, and cytokeratin 7; mucin staining using Periodic acid‐Schiff stain and Alcian blue for histological confirmation; ALK IHC to confirm the FISH results; and PD‐L1 IHC (using the PD‐L1 IHC 22C3 pharmDx, Agilent/Dako) for therapeutic purposes., PD‐L1 IHC was performed on 4 μm thick formalin‐fixed paraffin‐embedded (FFPE) tissue sections using the PD‐L1 clone 22C3 pharmDx kit and Dako Automated Link 48 platform (Agilent/Dako). .. Immunohistochemical staining for TTF‐1 (clone SP141, Ventana Medical Systems, Tucson, AZ, USA), p63 (clone 4A4), p40 (polyclonal anti p40; Diagnostic BioSystems, Pleasanton, CA, USA), cytokeratin 7 (clone SP52, Ventana), and ALK (clone 5A4, dilution 1:50, Leica Biosystems, Newcastle, UK) was performed using the Benchmark Ultra Autostainer (Roche Tissue Diagnostics, Tucson, AZ, USA) with an OptiView Universal DAB detection kit for ALK IHC and UltraView universal DAB detection kit for the other proteins (Ventana Medical Systems).

    Immunohistochemistry:

    Article Title: PD‐L1 expression in ROS1‐rearranged non‐small cell lung cancer: A study using simultaneous genotypic screening of EGFR, ALK, and ROS1
    Article Snippet: .. Additionally, the sample needed to have > 100 tumor cells for the PD‐L1 test and > 50 tumors cells for ALK and ROS1 FISH tests., In a tissue‐sparing manner, we also investigated an IHC panel including thyroid transcription factor 1 (TTF‐1), p63, p40, and cytokeratin 7; mucin staining using Periodic acid‐Schiff stain and Alcian blue for histological confirmation; ALK IHC to confirm the FISH results; and PD‐L1 IHC (using the PD‐L1 IHC 22C3 pharmDx, Agilent/Dako) for therapeutic purposes., PD‐L1 IHC was performed on 4 μm thick formalin‐fixed paraffin‐embedded (FFPE) tissue sections using the PD‐L1 clone 22C3 pharmDx kit and Dako Automated Link 48 platform (Agilent/Dako). .. Immunohistochemical staining for TTF‐1 (clone SP141, Ventana Medical Systems, Tucson, AZ, USA), p63 (clone 4A4), p40 (polyclonal anti p40; Diagnostic BioSystems, Pleasanton, CA, USA), cytokeratin 7 (clone SP52, Ventana), and ALK (clone 5A4, dilution 1:50, Leica Biosystems, Newcastle, UK) was performed using the Benchmark Ultra Autostainer (Roche Tissue Diagnostics, Tucson, AZ, USA) with an OptiView Universal DAB detection kit for ALK IHC and UltraView universal DAB detection kit for the other proteins (Ventana Medical Systems).

    Article Title: Immunohistochemical assays incorporating SP142 and 22C3 monoclonal antibodies for detection of PD-L1 expression in NSCLC patients with known status of EGFR and ALK genes
    Article Snippet: .. We compared the effectiveness of PD-L1 expression examination of two IHC assays with 22C3 (Dako) and SP142 antibodies (Ventana). .. IHC tests were performed in resected tissue samples and in cellblocks from bronchoscopy biopsies (formalin-fixed paraffin-embedded).

    Article Title: Multiple lung cancers including squamous cell carcinoma with strong PD-L1 expression and adenocarcinoma with EGFR exon 19 deletion: A case report
    Article Snippet: .. SQCC of the right middle lobe showed 100% tumor proportion score (TPS) for PD-L1 (Agilent Dako IHC 22C3 platform) ( B) and no expression of EGFR mutations (Roche cobas® EGFR Mutation Test v2) and anaplastic lymphoma kinase (ALK) rearrangements (Histofine ALK iAEP® Kit). .. Adenocarcinoma of the right lower lobe showed exon 19 deletion and no expression of PD-L1.

    Article Title: Any Place for Immunohistochemistry within the Predictive Biomarkers of Treatment in Lung Cancer Patients?
    Article Snippet: .. The 22C3 test (PD-L1 IHC 22C3 pharmDx, Agilent Technologies, Inc., Santa Clara, CA, USA) is currently the only test used as a companion diagnostic test (CDX) for the administration of pembrolizumab as first line treatement in advanced or metastatic NSCLC [ ]. ..

    Article Title: PD-L1 Expression Correlated with p53 Expression in Pediatric Glioblastoma Multiforme
    Article Snippet: The analysis was performed on a Dako Omnis IHC platform (GI100, Santa Clara, CA, USA). .. Selected reagents were used in the IHC analysis: PD-L1 IHC 22C3 pharmDx staining set (GE006) including monoclonal PD-L1 antibody 22C3 clone (Dako Omnis, Santa Clara, CA, USA), negative control (Dako Omnis, Santa Clara, CA, USA), high pH detective sys- tem EnVision Flex Mini Kit (Dako Omnis, Santa Clara, CA, USA, GV823), wash buffer (20x) (GC807, Dako Omnis, Santa Clara, CA, USA). .. In order to remove the paraffin, a low pH Envision Flex Target Retrieval Solution (Dako Omnis, Santa Clara, CA, USA) was used.

    Article Title: Evaluation of an online training tool for scoring programmed cell death ligand-1 (PD-L1) diagnostic tests for lung cancer
    Article Snippet: In the competence test set, the consensus scores for PD-L1 TC expression for samples stained using the VENTANA PD-L1 (SP263) assay were: 3 cases < 1%; 3 cases ≥1– < 25%; 3 cases ≥25– < 50%; 9 cases ≥50%. .. For samples stained using the Dako PD-L1 IHC PharmDx 22C3 assay, expression was classified as follows: 2 cases < 1%; 6 cases ≥1– < 25%; 4 cases ≥25– < 50%; 6 cases ≥50%. ..

    Staining:

    Article Title: PD‐L1 expression in ROS1‐rearranged non‐small cell lung cancer: A study using simultaneous genotypic screening of EGFR, ALK, and ROS1
    Article Snippet: .. Additionally, the sample needed to have > 100 tumor cells for the PD‐L1 test and > 50 tumors cells for ALK and ROS1 FISH tests., In a tissue‐sparing manner, we also investigated an IHC panel including thyroid transcription factor 1 (TTF‐1), p63, p40, and cytokeratin 7; mucin staining using Periodic acid‐Schiff stain and Alcian blue for histological confirmation; ALK IHC to confirm the FISH results; and PD‐L1 IHC (using the PD‐L1 IHC 22C3 pharmDx, Agilent/Dako) for therapeutic purposes., PD‐L1 IHC was performed on 4 μm thick formalin‐fixed paraffin‐embedded (FFPE) tissue sections using the PD‐L1 clone 22C3 pharmDx kit and Dako Automated Link 48 platform (Agilent/Dako). .. Immunohistochemical staining for TTF‐1 (clone SP141, Ventana Medical Systems, Tucson, AZ, USA), p63 (clone 4A4), p40 (polyclonal anti p40; Diagnostic BioSystems, Pleasanton, CA, USA), cytokeratin 7 (clone SP52, Ventana), and ALK (clone 5A4, dilution 1:50, Leica Biosystems, Newcastle, UK) was performed using the Benchmark Ultra Autostainer (Roche Tissue Diagnostics, Tucson, AZ, USA) with an OptiView Universal DAB detection kit for ALK IHC and UltraView universal DAB detection kit for the other proteins (Ventana Medical Systems).

    Article Title: PD-L1 Expression Correlated with p53 Expression in Pediatric Glioblastoma Multiforme
    Article Snippet: The analysis was performed on a Dako Omnis IHC platform (GI100, Santa Clara, CA, USA). .. Selected reagents were used in the IHC analysis: PD-L1 IHC 22C3 pharmDx staining set (GE006) including monoclonal PD-L1 antibody 22C3 clone (Dako Omnis, Santa Clara, CA, USA), negative control (Dako Omnis, Santa Clara, CA, USA), high pH detective sys- tem EnVision Flex Mini Kit (Dako Omnis, Santa Clara, CA, USA, GV823), wash buffer (20x) (GC807, Dako Omnis, Santa Clara, CA, USA). .. In order to remove the paraffin, a low pH Envision Flex Target Retrieval Solution (Dako Omnis, Santa Clara, CA, USA) was used.

    Article Title: Evaluation of an online training tool for scoring programmed cell death ligand-1 (PD-L1) diagnostic tests for lung cancer
    Article Snippet: In the competence test set, the consensus scores for PD-L1 TC expression for samples stained using the VENTANA PD-L1 (SP263) assay were: 3 cases < 1%; 3 cases ≥1– < 25%; 3 cases ≥25– < 50%; 9 cases ≥50%. .. For samples stained using the Dako PD-L1 IHC PharmDx 22C3 assay, expression was classified as follows: 2 cases < 1%; 6 cases ≥1– < 25%; 4 cases ≥25– < 50%; 6 cases ≥50%. ..

    Formalin-fixed Paraffin-Embedded:

    Article Title: PD‐L1 expression in ROS1‐rearranged non‐small cell lung cancer: A study using simultaneous genotypic screening of EGFR, ALK, and ROS1
    Article Snippet: .. Additionally, the sample needed to have > 100 tumor cells for the PD‐L1 test and > 50 tumors cells for ALK and ROS1 FISH tests., In a tissue‐sparing manner, we also investigated an IHC panel including thyroid transcription factor 1 (TTF‐1), p63, p40, and cytokeratin 7; mucin staining using Periodic acid‐Schiff stain and Alcian blue for histological confirmation; ALK IHC to confirm the FISH results; and PD‐L1 IHC (using the PD‐L1 IHC 22C3 pharmDx, Agilent/Dako) for therapeutic purposes., PD‐L1 IHC was performed on 4 μm thick formalin‐fixed paraffin‐embedded (FFPE) tissue sections using the PD‐L1 clone 22C3 pharmDx kit and Dako Automated Link 48 platform (Agilent/Dako). .. Immunohistochemical staining for TTF‐1 (clone SP141, Ventana Medical Systems, Tucson, AZ, USA), p63 (clone 4A4), p40 (polyclonal anti p40; Diagnostic BioSystems, Pleasanton, CA, USA), cytokeratin 7 (clone SP52, Ventana), and ALK (clone 5A4, dilution 1:50, Leica Biosystems, Newcastle, UK) was performed using the Benchmark Ultra Autostainer (Roche Tissue Diagnostics, Tucson, AZ, USA) with an OptiView Universal DAB detection kit for ALK IHC and UltraView universal DAB detection kit for the other proteins (Ventana Medical Systems).

    Expressing:

    Article Title: Immunohistochemical assays incorporating SP142 and 22C3 monoclonal antibodies for detection of PD-L1 expression in NSCLC patients with known status of EGFR and ALK genes
    Article Snippet: .. We compared the effectiveness of PD-L1 expression examination of two IHC assays with 22C3 (Dako) and SP142 antibodies (Ventana). .. IHC tests were performed in resected tissue samples and in cellblocks from bronchoscopy biopsies (formalin-fixed paraffin-embedded).

    Article Title: Multiple lung cancers including squamous cell carcinoma with strong PD-L1 expression and adenocarcinoma with EGFR exon 19 deletion: A case report
    Article Snippet: .. SQCC of the right middle lobe showed 100% tumor proportion score (TPS) for PD-L1 (Agilent Dako IHC 22C3 platform) ( B) and no expression of EGFR mutations (Roche cobas® EGFR Mutation Test v2) and anaplastic lymphoma kinase (ALK) rearrangements (Histofine ALK iAEP® Kit). .. Adenocarcinoma of the right lower lobe showed exon 19 deletion and no expression of PD-L1.

    Article Title: Evaluation of an online training tool for scoring programmed cell death ligand-1 (PD-L1) diagnostic tests for lung cancer
    Article Snippet: In the competence test set, the consensus scores for PD-L1 TC expression for samples stained using the VENTANA PD-L1 (SP263) assay were: 3 cases < 1%; 3 cases ≥1– < 25%; 3 cases ≥25– < 50%; 9 cases ≥50%. .. For samples stained using the Dako PD-L1 IHC PharmDx 22C3 assay, expression was classified as follows: 2 cases < 1%; 6 cases ≥1– < 25%; 4 cases ≥25– < 50%; 6 cases ≥50%. ..

    Mutagenesis:

    Article Title: Multiple lung cancers including squamous cell carcinoma with strong PD-L1 expression and adenocarcinoma with EGFR exon 19 deletion: A case report
    Article Snippet: .. SQCC of the right middle lobe showed 100% tumor proportion score (TPS) for PD-L1 (Agilent Dako IHC 22C3 platform) ( B) and no expression of EGFR mutations (Roche cobas® EGFR Mutation Test v2) and anaplastic lymphoma kinase (ALK) rearrangements (Histofine ALK iAEP® Kit). .. Adenocarcinoma of the right lower lobe showed exon 19 deletion and no expression of PD-L1.

    Diagnostic Assay:

    Article Title: Any Place for Immunohistochemistry within the Predictive Biomarkers of Treatment in Lung Cancer Patients?
    Article Snippet: .. The 22C3 test (PD-L1 IHC 22C3 pharmDx, Agilent Technologies, Inc., Santa Clara, CA, USA) is currently the only test used as a companion diagnostic test (CDX) for the administration of pembrolizumab as first line treatement in advanced or metastatic NSCLC [ ]. ..

    Article Title: Use of the 22C3 anti–PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms
    Article Snippet: In patients with metastatic NSCLC and no prior systemic therapy, pembrolizumab was recently approved in the United States for the treatment of patients with PD-L1 expression ≥50% based on the results of the KEYNOTE-024 (NCT02142738) study [ ]. .. Based on these data, pembrolizumab was approved in conjunction with a companion diagnostic test, the PD-L1 IHC 22C3 pharmDx assay (Dako, Carpinteria, CA) for use on the Dako Autostainer Link 48 (ASL48) platform [ , ]. .. However, pathology laboratories without the ASL48 platform are currently unable to provide PD-L1 immunohistochemistry (IHC) staining to identify patients with NSCLC suitable for treatment with pembrolizumab.

    Negative Control:

    Article Title: PD-L1 Expression Correlated with p53 Expression in Pediatric Glioblastoma Multiforme
    Article Snippet: The analysis was performed on a Dako Omnis IHC platform (GI100, Santa Clara, CA, USA). .. Selected reagents were used in the IHC analysis: PD-L1 IHC 22C3 pharmDx staining set (GE006) including monoclonal PD-L1 antibody 22C3 clone (Dako Omnis, Santa Clara, CA, USA), negative control (Dako Omnis, Santa Clara, CA, USA), high pH detective sys- tem EnVision Flex Mini Kit (Dako Omnis, Santa Clara, CA, USA, GV823), wash buffer (20x) (GC807, Dako Omnis, Santa Clara, CA, USA). .. In order to remove the paraffin, a low pH Envision Flex Target Retrieval Solution (Dako Omnis, Santa Clara, CA, USA) was used.

    Transmission Electron Microscopy:

    Article Title: PD-L1 Expression Correlated with p53 Expression in Pediatric Glioblastoma Multiforme
    Article Snippet: The analysis was performed on a Dako Omnis IHC platform (GI100, Santa Clara, CA, USA). .. Selected reagents were used in the IHC analysis: PD-L1 IHC 22C3 pharmDx staining set (GE006) including monoclonal PD-L1 antibody 22C3 clone (Dako Omnis, Santa Clara, CA, USA), negative control (Dako Omnis, Santa Clara, CA, USA), high pH detective sys- tem EnVision Flex Mini Kit (Dako Omnis, Santa Clara, CA, USA, GV823), wash buffer (20x) (GC807, Dako Omnis, Santa Clara, CA, USA). .. In order to remove the paraffin, a low pH Envision Flex Target Retrieval Solution (Dako Omnis, Santa Clara, CA, USA) was used.

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 97
    Agilent technologies peroxidase blocking reagent
    Peroxidase Blocking Reagent, supplied by Agilent technologies, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/peroxidase blocking reagent/product/Agilent technologies
    Average 97 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    peroxidase blocking reagent - by Bioz Stars, 2021-04
    97/100 stars
      Buy from Supplier

    86
    Agilent technologies endogenous peroxidase activity
    Endogenous Peroxidase Activity, supplied by Agilent technologies, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/endogenous peroxidase activity/product/Agilent technologies
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    endogenous peroxidase activity - by Bioz Stars, 2021-04
    86/100 stars
      Buy from Supplier

    86
    Agilent technologies endogenous peroxidase inhibitor
    Endogenous Peroxidase Inhibitor, supplied by Agilent technologies, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/endogenous peroxidase inhibitor/product/Agilent technologies
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    endogenous peroxidase inhibitor - by Bioz Stars, 2021-04
    86/100 stars
      Buy from Supplier

    Image Search Results